Fibroblast activation plays an important role in initiating the inflammatory response. Phenotypic attributes of fibroblasts from specific anatomic regions are thought to underlie the peculiar pattern of manifestations associated with certain diseases. Other fibroblast characteristics appear global, such as the expression of chemoattractants including IL-16, a CD4-specific ligand and RANTES, a C-C chemokine. We have found that fibroblasts from patients with the Graves' disease (GD), when treated with their IgGs (GD-IgG), become activated and express high levels of IL-16 and RANTES and in so doing provoke the migration of T cells. Control fibroblasts from donors without autoimmune disease fail to respond to these IgGs. GD-IgGs, which are rare in control sera, appear to be binding to the insulin-like growth factor-1 receptor (IGF-1R) displayed on fibroblasts. We hypothesize that IGF-1R represents an important activational self-antigen. Its ligation with GD-IgG up-regulates chemoattractant expression in fibroblasts. Further, we hypothesize that the IGF-1R display by disease-derived cultures in some way differs from that on control fibroblasts. These inductions could underlie T cell infiltration in GD. We now propose the following studies to test our central hypothesis.
Specific aims : (1) To define the mechanisms involved in the up-regulation by anti-IGF-1R Abs (i.e. GD-IgG) of IL-16 and RANTES expression in GD- fibroblasts by assessing transcriptional and translational regulation and cell signaling through IGF-1R. (2) To determine whether fibroblasts from patients with GD express functionally different IGF-1R from control fibroblasts, we will perform IGF-1 binding studies, northern and western blot analysis of IGF-1R alpha and beta subunit levels and examine IGF-1R tyrosine phosphorylation. (3) To determine whether serum and tissue levels of IL-16 and RANTES are higher in GD by performing ELISA, in situ hybridization and immunohistochemical studies. (4) To determine whether GD-IgG induces chemoattractant expression in vivo in xenotransplanted human orbital tissue from patients with GD in SCID mice. We believe that important insights into disease pathogenesis and identification of novel therapeutic targets will emerge from these studies. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK063121-05
Application #
7430451
Study Section
Endocrinology Study Section (END)
Program Officer
Blondel, Olivier
Project Start
2004-07-01
Project End
2009-03-31
Budget Start
2008-06-01
Budget End
2009-03-31
Support Year
5
Fiscal Year
2008
Total Cost
$332,060
Indirect Cost
Name
La Biomed Research Institute/ Harbor UCLA Medical Center
Department
Type
DUNS #
069926962
City
Torrance
State
CA
Country
United States
Zip Code
90502
Smith, Terry J (2018) Challenges in Orphan Drug Development: Identification of Effective Therapy for Thyroid-Associated Ophthalmopathy. Annu Rev Pharmacol Toxicol :
Smith, Terry J; Kahaly, George J; Ezra, Daniel G et al. (2017) Teprotumumab for Thyroid-Associated Ophthalmopathy. N Engl J Med 376:1748-1761
Chen, Hong; Shan, Shannon J C; Mester, Tünde et al. (2015) TSH-Mediated TNF? Production in Human Fibrocytes Is Inhibited by Teprotumumab, an IGF-1R Antagonist. PLoS One 10:e0130322
Lee, Brian J; Atkins, Stephen; Ginter, Anna et al. (2015) Increased CD40+ Fibrocytes in Patients With Idiopathic Orbital Inflammation. Ophthal Plast Reconstr Surg 31:202-6
Stein, Joshua D; Childers, David; Gupta, Shivani et al. (2015) Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease. JAMA Ophthalmol 133:290-6
Kristensen, Birte; Hegedüs, Laszlo; Lundy, Steven K et al. (2015) Characterization of Regulatory B Cells in Graves' Disease and Hashimoto's Thyroiditis. PLoS One 10:e0127949
Kristensen, B; Hegedüs, L; Madsen, H O et al. (2015) Altered balance between self-reactive T helper (Th)17 cells and Th10 cells and between full-length forkhead box protein 3 (FoxP3) and FoxP3 splice variants in Hashimoto's thyroiditis. Clin Exp Immunol 180:58-69
McCoy, Allison N; Kim, Denise S; Gillespie, Erin F et al. (2014) Rituximab (Rituxan) therapy for severe thyroid-associated ophthalmopathy diminishes IGF-1R(+) T cells. J Clin Endocrinol Metab 99:E1294-9
Wang, Yao; Smith, Terry J (2014) Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy. Invest Ophthalmol Vis Sci 55:1735-48
Chen, Hong; Mester, Tünde; Raychaudhuri, Nupur et al. (2014) Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes. J Clin Endocrinol Metab 99:E1635-40

Showing the most recent 10 out of 66 publications